Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Income from Discontinued Operations 3 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2022

Agios Pharm Income from Discontinued Operations 3 year CAGR is NA for the Trailing 12 Months (TTM) ending September 30, 2022. Income from Discontinued Operations is the income generated by a segment of a business that has been or will be discontinued. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Agios Pharm Income from Discontinued Operations for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -3.98 M, a -100.05% change year over year.
Agios Pharm Income from Discontinued Operations for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 7.86 B.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends